Case closed: Neutrons settle 40-year debate on enzyme for drug design
Filter News
Area of Research
News Type
Media Contacts
OAK RIDGE, Tenn., March 20, 2019—Direct observations of the structure and catalytic mechanism of a prototypical kinase enzyme—protein kinase A or PKA—will provide researchers and drug developers with significantly enhanced abilities to understand and treat fatal diseases and neurological disorders such as cancer, diabetes, and cystic fibrosis.
With the production of 50 grams of plutonium-238, researchers at the Department of Energy’s Oak Ridge National Laboratory have restored a U.S. capability dormant for nearly 30 years and set the course to provide power for NASA and other missions.